PTC Therapeutics, Inc.PTCT presented data from the phase III ACT DMD study on Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). Although Translarna was safe and generally well tolerated, the primary endpoint was not statistically